GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (OTCPK:BMXMF) » Definitions » Sale Of Investment

BMXMF (BioMerieux) Sale Of Investment : $0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Sale Of Investment?

BioMerieux's sale of investment for the six months ended in Jun. 2024 was $0 Mil. It means BioMerieux gained $0 Mil from selling investments. BioMerieux's sale of investment for the trailing twelve months (TTM) ended in Jun. 2024 was $0 Mil.

Compared with last quarter ($0 Mil in Dec. 2023 ), BioMerieux gained the same money from selling investments in Jun. 2024 ($0 Mil).


BioMerieux Sale Of Investment Historical Data

The historical data trend for BioMerieux's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Sale Of Investment Chart

BioMerieux Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.96

BioMerieux Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioMerieux Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioMerieux Sale Of Investment Related Terms

Thank you for viewing the detailed overview of BioMerieux's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


BioMerieux Business Description

Traded in Other Exchanges
Address
Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

BioMerieux Headlines

From GuruFocus

Q1 2020 Biomerieux SA Corporate Sales Call Transcript

By GuruFocus Research 02-12-2024

Q3 2021 Biomerieux SA Business Review Call Transcript

By GuruFocus Research 02-12-2024

Q3 2020 Biomerieux SA Business Review Call Transcript

By GuruFocus Research 02-12-2024

Full Year 2022 Biomerieux SA Earnings Call Transcript

By GuruFocus Research 02-12-2024

bioM�rieux Introduces GENE-UP� ENVIROPRO�

By PRNewswire PRNewswire 02-02-2023

Half Year 2021 Biomerieux SA Earnings Call Transcript

By GuruFocus Research 02-12-2024

Half Year 2023 Biomerieux SA Earnings Call Transcript

By GuruFocus Research 02-12-2024

Full Year 2019 Biomerieux SA Earnings Call Transcript

By GuruFocus Research 02-12-2024